Praxis Precision Medicines to Participate in Upcoming Fireside Chat

Rhea-AI Summary

Praxis Precision Medicines (NASDAQ: PRAX) announced an expert fireside chat on November 24, 2025 at 1:00 PM EST to discuss a deep dive into clinical data for ulixacaltamide. The event will be hosted by HC Wainwright analyst Doug Tsao and feature UCSF statistician Prof. Chuck McCullough alongside Praxis CEO Marcio Souza. The session focuses on interpretation of ulixacaltamide clinical results and will include an analyst-led discussion; registration is available via the company’s provided link.

News Market Reaction

-13.33% 3.5x vol

41 alerts

-13.33% News Effect

-9.9% Trough in 4 hr 52 min

-$697M Valuation Impact

$4.53B Market Cap

3.5x Rel. Volume

On the day this news was published, PRAX declined 13.33%, reflecting a significant negative market reaction. Argus tracked a trough of -9.9% from its starting point during tracking. Our momentum scanner triggered 41 alerts that day, indicating elevated trading interest and price volatility. This price movement removed approximately $697M from the company's valuation, bringing the market cap to $4.53B at that time. Trading volume was very high at 3.5x the daily average, suggesting heavy selling pressure.

Data tracked by StockTitan Argus on the day of publication.

BOSTON, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that HCWainwright analyst Doug Tsao will host an expert call on Deep Dive into Praxis’ Ulixacaltamide Data with statistician Prof. Chuck McCullogh, University of California, San Francisco on November 24, 2025 at 1:00pm EST which will be joined by Marcio Souza, Praxis’ CEO.

The registration link can be found here.

About Praxis
Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across epilepsy and movement disorders, with four clinical-stage product candidates. For more information, please visit www.praxismedicines.com and follow us on Facebook, Instagram, LinkedIn and Twitter/X.

Investor Contact:
Praxis Precision Medicines
investors@praxismedicines.com
857-702-9452

Media Contact:
Dan Ferry
Life Science Advisors
Daniel@lifesciadvisors.com
617-430-7576

FAQ

When is Praxis (PRAX) presenting its ulixacaltamide data discussion?

The expert call is scheduled for November 24, 2025 at 1:00 PM EST.

Who will speak on the Praxis (PRAX) ulixacaltamide expert call?

Speakers include HC Wainwright analyst Doug Tsao, UCSF statistician Prof. Chuck McCullough, and Praxis CEO Marcio Souza.

How can investors register for the Praxis (PRAX) ulixacaltamide fireside chat?

Investors can register using the registration link provided by Praxis on its investor relations or event announcement.

What will the Praxis (PRAX) expert call on November 24 cover?

The call will be a deep dive into ulixacaltamide clinical data, focusing on statistical interpretation and results discussion.

Will the Praxis (PRAX) event include management commentary on ulixacaltamide?

Yes; Praxis CEO Marcio Souza will join the analyst and statistician for the discussion.